申请人:Allergan, Inc.
公开号:US20160355527A1
公开(公告)日:2016-12-08
The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.